Latest Industry Insights

Discover how advanced drug delivery technologies are revolutionizing biotech, enabling safe, targeted cell therapy with fewer side effects.

In this article, ReiThera's scientific and operational leaders discuss ReiThera’s proprietary platforms, process development strategy and its evolving role as a CDMO partner in the advanced therapies landscape.

Immuto Scientific’s structural surfaceomics platform reveals how wild-type proteins adopt disease-specific shapes that drive pathology. Immuto identifies previously invisible drug targets and designs conformation-selective therapies.

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the reach of CAR T-cell therapies into solid tumor indications.

In this interview, we explore how Sonrai is advancing reproducible science, enabling cross-disciplinary collaboration and shaping the future of AI-powered drug discovery.

Technology Networks spoke with Dr. Mark Van Oene, chief operating officer at PacBio, about an ambitious population genomics effort – the Korean Pangenome Reference Project.

Technology Networks asked a selection of start-up companies featured in the ELRIG Drug Discovery 2025 Breakthrough Zone how their technology could help realize the full capabilities of precision medicine.

At this year’s American Society of Human Genetics (ASHG) meeting, Ultima Genomics drew attention for its ambitious goal of making large-scale omics research more accessible and affordable.

In this Q&A, Pratt discusses a recent study comparing multiplex droplet digital PCR (ddPCR) with traditional quantitative PCR (qPCR), highlighting key methodological differences, assay validation strategies and the advantages of ddPCR.

At ASHG, Illumina launches 5-base and shows exciting results from constellation, a breakthrough technology offering long-range genomic insights from unfragmented DNA.